Amgen's cancer drug combo cut death risk by 58% in lung cancer trial
Doctors combined powerful medicines from Amgen Inc. and AstraZeneca Plc and found they allowed patients with an aggressive form of lung cancer to live eight months longer.
3 across the spectrum. Choose a side on the bar to jump to it.
National story. 3 articles from 3 sources. Updated 7d ago.
How each side is putting it
Left
2 sourcesCenter
0 sourcesNo Center coverage yet.
A blind spot on this side of the story.